RL-Cervix.Net: A Hybrid Lightweight Model Integrating Reinforcement Learning for Cervical Cell Classification

<b>Background:</b> Reinforcement learning (RL) represents a significant advancement in artificial intelligence (AI), particularly for complex sequential decision-making challenges. Its capability to iteratively refine decisions makes it ideal for applications in medicine, such as the detection of cervical cancer; a major cause of mortality among women globally. The Pap smear test, a crucial diagnostic tool for cervical cancer, benefits from enhancements in AI, facilitating the development of automated diagnostic systems that improve screening effectiveness. This research introduces RL-Cervix.Net, a hybrid model integrating RL with convolutional neural network (CNN) technologies, aimed at elevating the precision and efficiency of cervical cancer screenings. <b>Methods:</b> RL-Cervix.Net combines the robust ResNet-50 architecture with a reinforcement learning module tailored for the unique challenges of cytological image analysis. The model was trained and validated using three extensive public datasets to ensure its effectiveness under realistic conditions. A novel application of RL for dynamic feature refinement and adjustment based on reward functions was employed to optimize the detection capabilities of the model. <b>Results:</b> The innovative integration of RL into the CNN framework allowed RL-Cervix.Net to achieve an unprecedented classification accuracy of 99.98% in identifying atypical cells indicative of cervical lesions. The model demonstrated superior accuracy and interpretability compared to existing methods, addressing variability and complexities inherent in cytological images. <b>Conclusions:</b> The RL-Cervix.Net model marks a significant breakthrough in the application of AI for medical diagnostics, particularly in the early detection of cervical cancer. By significantly improving diagnostic accuracy and efficiency, RL-Cervix.Net has the potential to enhance patient outcomes through earlier and more precise identification of the disease, ultimately contributing to reduced mortality rates and improved healthcare delivery.